Close
4

Quotient Sciences Quotient Sciences

X

Company profile for Relmada Therapeutics

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage...
Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage our considerable industry and development experience, and disease knowledge to identify, develop and commercialize product candidates for CNS conditions with high unmet needs.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Relmada Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Relmada Therapeutics, Inc. 880 Third Avenue 12th Floor New York, NY 10022
Telephone
Telephone
646-876-3459

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY